Advertisement

Topics

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

12:31 EST 13 Dec 2018 | Investing News Network

Corcept Therapeutics (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome).  The patent will expire in 2037. As quoted in … Continued

The post Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome appeared first on Investing News Network.

Original Article: Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

NEXT ARTICLE

More From BioPortfolio on "Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome"

Advertisement
Quick Search
Advertisement
Advertisement